# A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

> **NCT05787574** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 39 (estimated)

## Conditions studied

- Primary Immune Regulatory Disorder
- Autoimmune Lymphoproliferative
- Immune System Diseases

## Interventions

- **DRUG:** Emapalumab
- **DRUG:** Fludarabine and Dexamethasone
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT05787574
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05787574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05787574, "A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05787574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*